N6B.F Labcorp Holdings Inc.
- Market cap
- EUR 27.0B
- P/E
- 31.8x
- P/B
- 3.38x
- ROE
- 12.6%
- Dividend yield
- 0.78%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is N6B.F undervalued?
Graham numberN6B.F trades 118.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Labcorp Holdings Inc. fundamental analysis
No fundamental analysis for Labcorp Holdings Inc. yet.
Labcorp Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising…
Full company profileLabcorp Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Labcorp Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 13.1B | 11.9B | 12.2B | 13.0B | 14.0B | 14.8B |
| Gross Profit | 4.99B | 3.71B | 3.36B | 3.62B | 4.01B | 4.31B |
| Operating Income | 3.07B | 1.75B | 1.12B | 1.14B | 1.52B | 1.68B |
| EBITDA | - | 1.95B | 1.35B | 1.81B | 2.01B | 2.33B |
| Net Income | 2.38B | 1.28B | 418M | 746M | 877M | 1.12B |
| EPS | 26 | 15 | 4.98 | 8.94 | 11 | 14 |
| Balance Sheet | ||||||
| Total Assets | 20.4B | 20.2B | 16.7B | 18.4B | 18.4B | 18.9B |
| Total Liabilities | 10.1B | 10.0B | 8.83B | 10.3B | 9.76B | 10.1B |
| Shareholders' Equity | 10.3B | 10.1B | 7.88B | 8.05B | 8.62B | 8.85B |
| Cash & Short-term Investments | 1.47B | 321M | 537M | 1.52B | 532M | 262M |
| Cash Flow | ||||||
| Operating Cash Flow | 3.11B | 1.96B | 1.33B | 1.59B | 1.64B | 1.60B |
| Capital Expenditure | 422M | 429M | 454M | 490M | 435M | 539M |
| Free Cash Flow | 2.69B | 1.53B | 874M | 1.10B | 1.21B | 1.06B |
| Ratios | ||||||
| ROE | 23.1% | 12.7% | 5.3% | 9.3% | 10.2% | 12.6% |
| ROA | 11.7% | 6.3% | 2.5% | 4.1% | 4.8% | 5.9% |
| Net Profit Margin | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% | 7.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Labcorp Holdings Inc. dividends
- Dividend yield
- 0.78%
- Forward dividend
- 2.57 EUR
- Payout ratio
- 27.5%
- Ex-dividend date
- Nov 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 241M | 2.93 | 27.5% |
| 2024 | USD 243M | 2.91 | 32.6% |
| 2023 | USD 254M | 3.03 | 60.8% |
| 2022 | USD 195M | 2.21 | 15.3% |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Dec 6, 2001.
Who owns Labcorp Holdings Inc.
- Insiders 0.35%
- Institutions 99.65%
- Public & others 0.00%
- Shares outstanding 81.2M
- Free float 80.8M
Labcorp Holdings Inc. company profile
- Company name
- Labcorp Holdings Inc.
- Ticker
- N6B.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 71,000
- Fiscal year end
- December
- Address
- 531 South Spring Street, Burlington, NC, United States, 27215
- Phone
- 336 229 1127
- Website
- labcorp.com
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Labcorp Holdings Inc. management
10- Mr. Adam H. SchechterPresident, CEO & Chairman · born 1965
- Ms. Julia A. WangExecutive VP & CFO · born 1971
- Dr. Brian J. Caveney J.D., M.D., M.P.H.Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer · born 1974
- Mr. Jonathan C. Meltzer Ph.D.Executive VP & COO
- Mr. Peter J. WilkinsonSenior VP & Chief Accounting Officer · born 1971
- Mr. Akinbolade Oyegunwa M.B.A., Ph.D.Executive VP and Chief Information & Technology Officer · born 1983
- Mr. Dewey Steadman C.F.A.Senior Vice President of Investor Relations
- Ms. Kathryn Wright KyleExecutive VP, Chief Legal Officer & Corporate Secretary · born 1971
- Ms. Amy B. SummyExecutive VP, Chief Marketing Officer & Consumer Health Lead · born 1966
- Ms. Anita Z. GrahamExecutive VP & Chief Human Resources Officer · born 1971